State legal innovations to encourage naloxone dispensing

Journal of the American Pharmacists Association

Volumn 57, Issue 2, 2017, Pages S180-S184

  Davis, Corey ^a   Carr, Derek ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

CRIMINAL JUSTICE; CRIMINAL LAW; DOCTOR PATIENT RELATION; DRUG INTOXICATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; LEGAL ASPECT; LEGAL LIABILITY; MEDICAL LIABILITY; NOTE; PHARMACIST ATTITUDE; PRESCRIPTION; PRESCRIPTIVE AUTHORITY; PROFESSIONAL DELEGATION; RISK REDUCTION; SCOPE OF PRACTICE; STANDING ORDER; COMPLICATION; DRUG CONTROL; DRUG OVERDOSE; GOVERNMENT; LEGISLATION AND JURISPRUDENCE; MORTALITY; OPIOID-RELATED DISORDERS; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PHARMACIST; PHARMACY; SUPPLY AND DISTRIBUTION; UNITED STATES;

ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; DRUG OVERDOSE; HUMANS; LIABILITY, LEGAL; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT CARE TEAM; PHARMACEUTICAL SERVICES; PHARMACISTS; STATE GOVERNMENT; UNITED STATES;

EID: 85020447008     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1016/j.japh.2016.11.007     Document Type: Note

References (36)

1. Rudd, R.A., Aleshire, N., Zibbell, J.E., Gladden, R.M., Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep 64:50-51 (2016), 1378–1382.
2. Chamberlain, J.M., Klein, B.L., A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 12:6 (1994), 650–660.
3. van Dorp, E.L., Yassen, A., Dahan, A., Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf 6:2 (2007), 125–132.
4. Michiels, C., Physiological and pathological responses to hypoxia. Am J Pathol 164:6 (2004), 1875–1882.
5. Davis, C.S., Southwell, J.K., Niehaus, V.R., Walley, A.Y., Dailey, M.W., Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med 21:10 (2014), 1173–1177.
6. Lim, J.K., Bratberg, J.P., Davis, C.S., Green, T.C., Walley, A.Y., Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med 10:5 (2016), 300–308.
7. National Association of Boards of Pharmacy. NABP issues policy statement supporting the pharmacist's role in increasing access to opioid overdose reversal drug. 2014 Available at: https://www.nabp.net/news/nabp-issues-policy-statement-supporting-the-pharmacist-s-role-in-increasing-access-to-opioid-overdose-reversal-drug Accessed September 12, 2015.
8. Davis, C.S., Carr, D., Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend 157 (2015), 112–120.
9. Prescription Drug Abuse Policy System. Naloxone overdose prevention laws. 2016 Available at: http://www.pdaps.org/dataset/overview/laws-regulating-administration-of-naloxone/ Accessed August 15, 2016.
10. Jones, C.M., Lurie, P.G., Compton, W.M., Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. Am J Public Health 106:4 (2016), 689–690.
11. Green, T.C., Dauria, E.F., Bratberg, J., Davis, C.S., Walley, A.Y., Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J, 12(1), 2015, 25.
12. Davis, C.S., Chang, S., Carr, D., Legal interventions to reduce overdose mortality: naloxone access and overdose Good Samaritan laws. Network for Public Health Law, 2015 Available at: https://www.networkforphl.org/_asset/qz5pvn/network-naloxone-10-4.pdf Accessed September 15, 2016.
13. Code of Federal Regulations. Title 21 C.F.R. Section 1306.04.
14. Blake, V., When is a patient-physician relation established?. AMA J Ethics, 14(5), 2012, 4.
15. Beletsky, L., Ruthazer, R., Macalino, G.E., Rich, J.D., Tan, L., Burris, S., Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health 84:1 (2007), 126–136.
16. Binswanger, I.A., Koester, S., Mueller, S.R., Gardner, E.M., Goddard, K., Glanz, J.M., Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med 30:12 (2015), 1837–1844.
17. Hogben, M., McCree, D.H., Golden, M.R., Patient-delivered partner therapy for sexually transmitted diseases as practiced by U.S. physicians. Sex Transm Dis 32:2 (2005), 101–105.
18. Workowski, K.A., Bolan, G.A., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64:RR-03 (2015), 1–137.
19. Kissinger, P.J., Expedited partner therapy for sexually transmitted diseases—are we there yet?. Sex Transm Dis 41:11 (2014), 695–697.
20. Cramer, R., Leichliter, J.S., Stenger, M.R., Loosier, P.S., Slive, L., Group, S.S.W., The legal aspects of expedited partner therapy practice: do state laws and policies really matter?. Sex Transm Dis 40:8 (2013), 657–662.
21. Centers for Disease Control and Prevention. Legal status of expedited partner therapy (EPT). 2016 Available at: http://www.cdc.gov/std/ept/legal/default.htm Accessed August 15, 2016.
22. Drug Store News. CVS Health to offer naloxone without prescription in 23 states by month's end. Drug Store News, March 7, 2016.
23. Walgreens leads fight against prescription drug abuse with new programs to help curb misuse of medications and the rise in overdose deaths, February 9, 2016 Available at: http://news.walgreens.com/press-releases/general-news/walgreens-leads-fight-against-prescription-drug-abuse-with-new-programs-to-help-curb-misuse-of-medications-and-the-rise-in-overdose-deaths.htm Accessed July 23, 2016.
24. Clause, S., Fudin, J., Mergner, A., Lutz, J.L., Kavanaugh, M.M., Fessler, K., et al. Prescribing privileges among pharmacists in Veterans Affairs medical centers. Am J Health Syst Pharm 58:12 (2001), 1143–1145.
25. Department of Health and Human Services. SGM 96–2: designation of pharmacists as primary care providers with prescriptive authority. 1996 Available at: https://www.ihs.gov/ihm/index.cfm?module=dsp_ihm_sgm_main&sgm=ihm_sgm_9602 Accessed September 12, 2016.
26. Wermeling, D.P., Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf 6:1 (2015), 20–31.
27. Davis, C.S., Carr, D., Southwell, J.K., Beletsky, L., Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am J Public Health, 2015, e1–e7.
28. Davis, C.S., Burris, S., Beletsky, L., Binswanger, I., Co-prescribing naloxone does not increase liability risk. Subst Abuse 37:4 (2016), 498–500.
29. Burris, S., Norland, J., Edlin, B.R., Legal aspects of providing naloxone to heroin users in the United States. In J Drug Policy 12:3 (2001), 237–248.
30. North Carolina General Statutes, Section 1A-1, Rule 9. N.C.G.S. § 1A-1 Rule 9. Available at: http://www.ncleg.net/gascripts/statutes/StatutesTOC.pl?Chapter=0001A. Accessed January 3, 2017.
31. Cicero, T.J., Ellis, M.S., Harney, J., Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med 373:18 (2015), 1789–1790.
32. Cicero, T.J., Kuehn, B.M., Driven by prescription drug abuse, heroin use increases among suburban and rural whites. JAMA 312:2 (2014), 118–119.
33. Tesoriero, J.M., Battles, H.B., Klein, S.J., Kaufman, E., Birkhead, G.S., Expanding access to sterile syringes through pharmacies: assessment of New York's Expanded Syringe Access Program. J Am Pharm Assoc (2003) 49:3 (2009), 407–416.
34. Rich, J.D., Martin, E.G., Macalino, G.E., Paul, R.V., McNamara, S., Taylor, L.E., Pharmacist support for selling syringes without a prescription to injection drug users in Rhode Island. J Am Pharm Assoc 42:6 Suppl 2 (2002), S58–S61.
35. Dowell, D., Haegerich, T.M., Chou, R., CDC guideline for prescribing opioids for chronic pain—United States. 2016. JAMA 315:15 (2016), 1624–1645.
36. Benyamin, R., Trescot, A.M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., et al. Opioid complications and side effects. Pain Physician 11:2 Suppl (2008), S105–S120.